PHARM.ASPHARM.ASAMS
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +12.60% | +13.20% | +42.29% | +25.92% | +29.61% |
| Gross Profit Growth | +16.89% | +19.92% | +50.29% | +27.58% | +32.23% |
| EBITDA Growth | +50.83% | +127.55% | +0.00% | +0.00% | +222.95% |
| Operating Income Growth | +115.30% | +1008.23% | +0.00% | +0.00% | +285.18% |
| Net Income Growth | -129.85% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -138.10% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -138.10% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -6.72% | -11.78% | -20.24% | -21.10% | +3.53% |
| Weighted Average Shares Diluted Growth | -6.72% | -11.78% | -20.24% | -21.10% | +3.53% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +176.21% | -23.41% | +0.00% | +0.00% | +228.74% |
| Free Cash Flow Growth | +177.40% | -22.41% | +0.00% | +0.00% | +240.83% |
| Receivables Growth | +18.95% | +56.43% | +22.71% | +4.32% | -9.53% |
| Inventory Growth | +16.44% | -1.83% | +6.20% | +7.64% | +7.89% |
| Asset Growth | -2.51% | -15.07% | -8.71% | +7.29% | +11.34% |
| Book Value per Share Growth | +15.30% | +14.54% | +30.28% | +44.68% | +13.21% |
| Debt Growth | -22.50% | -34.53% | -28.75% | +5.16% | +3.02% |
| R&D Expense Growth | -0.15% | +90.74% | +14.42% | +9.80% | +12.85% |
| SG&A Expenses Growth | +22.13% | -174.49% | +25.85% | +6.40% | +16.15% |